PURE Bioscience Q2 2026 Earnings Report

PURE Bioscience EPS Results

• Actual EPS: -$0.01
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

PURE Bioscience Revenue Results

• Actual Revenue: $0.44 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

PURE Bioscience Announcement Details

• Quarter: Q2 2026
• Date: 3/16/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

PURE Bioscience (OTCMKTS:PURE), Inc. develops and commercializes antimicrobial products based on its proprietary silver dihydrogen citrate (SDC) technology. The company’s formulations are designed to provide broad-spectrum antimicrobial activity while supporting applications where effective sanitation and surface treatment are required.

Its product portfolio has included disinfectants, sanitizers and antimicrobial solutions for hard-surface cleaning, food processing, healthcare, hospitality, institutional and commercial environments. PURE Bioscience has also offered products intended for use in food-safety and odor-control applications, with formulations and uses subject to applicable regulatory approvals.

The company markets its products primarily through business, industrial and institutional channels, including distributors and other commercial partners. PURE Bioscience is based in San Diego, California. Publicly available information about its current leadership and geographic operating footprint is limited, so no further management details are provided here.